Back to search results

SHIELD Portal for ER/PR-Positive Breast Cancer

This study is testing a new web and mobile app called the SHIELD portal. The portal offers educational materials, symptom tracking, and health tools to support women with hormone receptor-positive (ER/PR-positive) breast cancer who are receiving long-term endocrine therapy. We want to see how well we can enroll participants and how useful the SHIELD portal is. You might be able to join if you are a woman between 18 and 49 years old, diagnosed with stage 0-IIIa HR+ breast cancer, premenopausal, currently undergoing treatment, and can speak and read English. The main goal is to see how many people enroll in the study within three weeks.

Study design
This is a single-arm pilot study, meaning all 30 participants will receive access to the SHIELD portal. There is no comparison group. The study aims to assess the feasibility of enrolling participants.
What's involved
You would be screened for eligibility, then access and use the SHIELD web and mobile app. You would also complete survey assessments on the portal. Participation is expected to last 3 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, Enrollment Yield, is measured at up to 3 weeks. The study duration is 3 months, but specific follow-up after this period is not detailed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07482384

Supporting Health Including Endocrine Treatment for Long Duration

Recruiting
NAAges 18–49InterventionalSupportive care
Dana-Farber Cancer Institute
~30 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:SHIELD portal

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment Yield
Measured over up to 3 weeks

Conditions

Breast Cancer
Breast Cancer - Female
Breast Carcinoma
ER Positive Breast Cancer
PR-Positive Breast Cancer

Explore related trials

Breast CarcinomaHR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Ann H Partridge, MD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Ann H Partridge, MD, MPH
[email protected]
617-632-6800
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female
Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer
Premenopausal
In active treatment (including long-term endocrine therapy) at the time of enrollment
Able to speak, understand and read English
Access to a US-based mobile phone number
Cognitively able to complete study requirements
Ability to access medical records from treating hospital (DFCI)
Willing to provide cell phone number and/or email address and willing to receive email, mobile push notifications, and/or text messages from the study team

Exclusion

Individuals under age 18 or over age 50 at initial breast cancer diagnosis
Stage IV or metastatic breast cancer
Pregnant patients
Individuals who do not have a US mobile phone number
Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.

What this trial measures

  • Enrollment Yieldup to 3 weeks

    Enrollment yield is defined as the proportion of participants approached for the study intervention (SHIELD, Supporting Health Including Endocrine Treatment for Long Duration) who enroll.